Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

Carmelo is a top five SF ever if we going by eye test, stats, longevity, basketball evolution and ability 🤷🏽‍♂️ Skilled bully!

86,586 Aufrufe • vor 2 Jahren •via X (Twitter)

10 Kommentare

Profilbild von Spence
Spencevor 2 Jahren

Your eye test isn’t good. Basketball evolution? 🙄

Profilbild von Washed Gamer
Washed Gamervor 2 Jahren

“Melo is a top 5 SF ever if we just ignore facts” This is why Jamal Crawford is the best offensive shooting guard of all time

Profilbild von Legends of the Paul
Legends of the Paulvor 2 Jahren

🤣🤣🤣 The worst opinions on this app Bron, Bird, Baylor, Durant, Dr. J, Pippen, Hondo, Kawhi, Barry are all undeniably better Then there’s guys like Pierce, King, English, Worthy, Wilkins, Butler who are easily in the convo for equal or better. Another 🗑️ take

Profilbild von 💎M͜͡i͜͡t͜͡o͜͡M͜͡a͜͡g͜͡i͜͡c💎
💎M͜͡i͜͡t͜͡o͜͡M͜͡a͜͡g͜͡i͜͡c💎vor 2 Jahren

😂 if by eye test you mean watching a couple highlights of his middie pull-ups in each game and acting like that’s representative of the whole game

Profilbild von POLO ASSASSINS OUT NOW
POLO ASSASSINS OUT NOWvor 2 Jahren

Of course he is…is this an argument?

Profilbild von Dime Dropper
Dime Droppervor 2 Jahren

🤣🤣🤣🤣

Profilbild von Basketball Visionaries
Basketball Visionariesvor 2 Jahren

LeBron Bird Durant Dr.J Baylor Barry Havlicek Pippen Kawhi I’d argue that Carmelo is fighting Dominique for 10th

Profilbild von Andrew D
Andrew Dvor 2 Jahren

I’m a lifelong Knicks and Syracuse fan and can confidently say this is a 🤡 take. He’s not even a top 5 knick of all time, so he sure af isn’t a top 5 SF in nba history. Not close.

Profilbild von Ricky Chu
Ricky Chuvor 2 Jahren

Def not top 5 SF

Profilbild von Tripp
Trippvor 2 Jahren

“Nothing but net every time” Right. EVERY TIME. Hilarious takes.

Ähnliche Videos

Today’s guest on the Free Radicals podcast is Michael Ringel, JD PhD, COO Life Biosciences and former Managing Director at Boston Consulting Group. Michael is a leader in longevity and pharma who spent 25+ years advising top pharma companies on their R&D strategy. He is now COO at Life Biosciences where he is bringing the first ever partial epigenetic reprogramming therapy to human clinical trials - a major milestone for the longevity industry. In this episode, we discuss Michael’s insightful paper on why aging is an optimization by evolution, why that means it’s malleable, and how to push the longevity field forward. Michael also sits on the US board of Hevolution Foundation and on the board of the AFAR. Be sure to follow me and Eric Dai to stay up to date on the latest news in longevity biotech! 0:00 Intro 2:30 Why aging is an optimization by evolution 15:10 Why scientists miss the role of evolution in aging 19:31 Evidence that aging is a regulated process 24:40 Hormesis and adaptive stress responses 28:55 The promise of partial epigenetic reprogramming in humans 35:08 Life Bio's first therapy proceeding to clinical trials 47:47 Why targeting the eye, particularly glaucoma and NION, is a strategic choice 52:03 The pharma industry's perspective on anti-aging research 56:39 The importance of public engagement for funding and policy change 1:05:42 Reasons for optimism in longevity 1:08:26 Advice on how to have an impactful and interdisciplinary career 1:11:54 The ethical case for longevity 1:17:34 Concrete steps for audience members to support longevity research

Daniel Shur

16,988 Aufrufe • vor 5 Monaten